MedTrace Logo

AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia

NCT02675452 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 141

Last updated 2025-07-09

Study results available
· View outcomes & findings →

Summary

The main objectives are to evaluate the safety and tolerability of AMG 176 monotherapy in participants with relapsed or refractory multiple myeloma and participants with relapsed or refractory acute myeloid leukemia.

Conditions

Interventions

DRUG

AMG 176

Study Drug

DRUG

Azacitidine

Non-investigational product

DRUG

Itraconazole

Non-investigational product

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-13
Primary Completion
2024-05-27
Completion
2024-05-27
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • Germany
  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02675452 on ClinicalTrials.gov